Jelena Klawitter
Concepts (526)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 14 | 2024 | 260 | 4.250 |
Why?
| | Kidney | 20 | 2024 | 1466 | 2.570 |
Why?
| | Tandem Mass Spectrometry | 15 | 2024 | 538 | 2.470 |
Why?
| | Metabolomics | 20 | 2022 | 681 | 2.440 |
Why?
| | Cardiopulmonary Bypass | 10 | 2025 | 207 | 2.230 |
Why?
| | Immunosuppressive Agents | 15 | 2019 | 861 | 1.840 |
Why?
| | Chromatography, High Pressure Liquid | 14 | 2024 | 577 | 1.810 |
Why?
| | Oxidative Stress | 18 | 2020 | 1318 | 1.690 |
Why?
| | Cyclosporine | 10 | 2019 | 267 | 1.650 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 436 | 1.230 |
Why?
| | Metabolome | 8 | 2022 | 350 | 1.180 |
Why?
| | Sirolimus | 9 | 2019 | 268 | 1.130 |
Why?
| | Cardiac Surgical Procedures | 3 | 2022 | 526 | 1.090 |
Why?
| | Cyclophilins | 2 | 2017 | 39 | 1.060 |
Why?
| | Energy Metabolism | 8 | 2022 | 919 | 0.940 |
Why?
| | Proteomics | 14 | 2020 | 1106 | 0.930 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 802 | 0.920 |
Why?
| | Biomarkers | 22 | 2023 | 4095 | 0.900 |
Why?
| | Tryptophan | 5 | 2024 | 182 | 0.870 |
Why?
| | Endocannabinoids | 4 | 2025 | 64 | 0.760 |
Why?
| | TRPP Cation Channels | 2 | 2024 | 84 | 0.760 |
Why?
| | Kynurenine | 5 | 2024 | 114 | 0.760 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 925 | 0.760 |
Why?
| | Lovastatin | 2 | 2013 | 38 | 0.730 |
Why?
| | Pravastatin | 3 | 2023 | 41 | 0.700 |
Why?
| | Menopause | 3 | 2020 | 323 | 0.690 |
Why?
| | Arginine | 2 | 2024 | 260 | 0.680 |
Why?
| | Cannabinoids | 3 | 2024 | 167 | 0.670 |
Why?
| | Heart Defects, Congenital | 5 | 2025 | 828 | 0.660 |
Why?
| | Mass Spectrometry | 10 | 2021 | 737 | 0.640 |
Why?
| | Myocardium | 2 | 2017 | 895 | 0.640 |
Why?
| | Adenosine | 3 | 2018 | 221 | 0.600 |
Why?
| | Glomerular Filtration Rate | 10 | 2023 | 743 | 0.600 |
Why?
| | Signal Transduction | 11 | 2021 | 5047 | 0.600 |
Why?
| | Coronary Care Units | 1 | 2018 | 19 | 0.600 |
Why?
| | Piperazines | 3 | 2009 | 343 | 0.590 |
Why?
| | Pyrimidines | 4 | 2014 | 465 | 0.570 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 451 | 0.560 |
Why?
| | Tacrolimus | 4 | 2017 | 194 | 0.550 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 31 | 0.550 |
Why?
| | Urine | 1 | 2017 | 59 | 0.540 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 29 | 0.530 |
Why?
| | Alkaline Phosphatase | 2 | 2018 | 149 | 0.510 |
Why?
| | Length of Stay | 4 | 2025 | 1192 | 0.510 |
Why?
| | Mycophenolic Acid | 3 | 2014 | 117 | 0.510 |
Why?
| | Disease Models, Animal | 9 | 2024 | 4276 | 0.490 |
Why?
| | Animals | 42 | 2024 | 36882 | 0.490 |
Why?
| | Adenosine Monophosphate | 1 | 2016 | 66 | 0.490 |
Why?
| | Plasma | 1 | 2017 | 215 | 0.480 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 258 | 0.470 |
Why?
| | Male | 51 | 2025 | 67386 | 0.470 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.460 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 321 | 0.450 |
Why?
| | Kidney Transplantation | 10 | 2018 | 696 | 0.450 |
Why?
| | Female | 49 | 2025 | 73002 | 0.440 |
Why?
| | Limit of Detection | 7 | 2024 | 87 | 0.440 |
Why?
| | Chromatography, Liquid | 8 | 2024 | 437 | 0.430 |
Why?
| | Humans | 72 | 2025 | 136965 | 0.430 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.430 |
Why?
| | Endothelium | 1 | 2014 | 121 | 0.430 |
Why?
| | Kidney Diseases | 4 | 2021 | 407 | 0.420 |
Why?
| | Disease Progression | 7 | 2023 | 2708 | 0.420 |
Why?
| | Cell Proliferation | 4 | 2024 | 2456 | 0.420 |
Why?
| | Oxylipins | 2 | 2025 | 40 | 0.410 |
Why?
| | Inflammation | 9 | 2025 | 2831 | 0.410 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 120 | 0.410 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.390 |
Why?
| | Proteome | 3 | 2016 | 470 | 0.390 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 36 | 0.380 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 75 | 0.380 |
Why?
| | Oncogene Proteins | 1 | 2012 | 57 | 0.380 |
Why?
| | Dinoprost | 5 | 2019 | 44 | 0.380 |
Why?
| | Mutation | 2 | 2022 | 3975 | 0.370 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 850 | 0.360 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 279 | 0.360 |
Why?
| | Postoperative Complications | 3 | 2021 | 2622 | 0.350 |
Why?
| | Rats | 16 | 2024 | 5544 | 0.350 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 162 | 0.350 |
Why?
| | Plant Extracts | 2 | 2024 | 206 | 0.350 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 255 | 0.340 |
Why?
| | Mitochondria | 1 | 2017 | 949 | 0.340 |
Why?
| | Nitric Oxide | 4 | 2024 | 883 | 0.340 |
Why?
| | Purines | 2 | 2022 | 176 | 0.340 |
Why?
| | Hypoxia | 6 | 2024 | 1108 | 0.330 |
Why?
| | Blotting, Western | 6 | 2012 | 1216 | 0.320 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 613 | 0.320 |
Why?
| | Mice, Inbred C57BL | 12 | 2023 | 5733 | 0.320 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 323 | 0.310 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 458 | 0.310 |
Why?
| | Prostaglandins | 3 | 2022 | 96 | 0.310 |
Why?
| | Theophylline | 2 | 2020 | 40 | 0.300 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 64 | 0.300 |
Why?
| | Mice | 19 | 2024 | 17705 | 0.300 |
Why?
| | Glycolysis | 4 | 2012 | 319 | 0.300 |
Why?
| | Autophagy | 3 | 2024 | 286 | 0.300 |
Why?
| | Infant | 10 | 2025 | 9392 | 0.300 |
Why?
| | Antineoplastic Agents | 3 | 2009 | 2111 | 0.290 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2021 | 18 | 0.290 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2021 | 23 | 0.290 |
Why?
| | Mice, Knockout | 7 | 2023 | 2999 | 0.280 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3393 | 0.280 |
Why?
| | Vascular Diseases | 2 | 2021 | 242 | 0.280 |
Why?
| | Amino Acids | 2 | 2025 | 493 | 0.280 |
Why?
| | Case-Control Studies | 7 | 2024 | 3556 | 0.270 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 791 | 0.270 |
Why?
| | Blood Vessels | 2 | 2019 | 182 | 0.260 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3266 | 0.260 |
Why?
| | Time Factors | 8 | 2022 | 6786 | 0.260 |
Why?
| | Infant, Newborn | 8 | 2025 | 6051 | 0.250 |
Why?
| | Rats, Wistar | 6 | 2018 | 448 | 0.250 |
Why?
| | Microsomes, Liver | 2 | 2019 | 81 | 0.240 |
Why?
| | Prospective Studies | 12 | 2025 | 7512 | 0.240 |
Why?
| | Deoxyglucose | 2 | 2024 | 52 | 0.240 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2266 | 0.230 |
Why?
| | Swine | 3 | 2022 | 778 | 0.230 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 71 | 0.230 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.230 |
Why?
| | Young Adult | 12 | 2023 | 13218 | 0.230 |
Why?
| | Mitragyna | 1 | 2024 | 7 | 0.230 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 69 | 0.230 |
Why?
| | Alkaloids | 1 | 2024 | 31 | 0.230 |
Why?
| | Dronabinol | 2 | 2024 | 233 | 0.220 |
Why?
| | Treatment Outcome | 8 | 2021 | 10664 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 22 | 0.210 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.210 |
Why?
| | Arachidonic Acids | 1 | 2024 | 64 | 0.210 |
Why?
| | Graft Rejection | 4 | 2017 | 571 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 37 | 0.200 |
Why?
| | Adult | 17 | 2023 | 37715 | 0.200 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 24 | 0.200 |
Why?
| | Analgesia | 1 | 2024 | 94 | 0.200 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2012 | 111 | 0.200 |
Why?
| | Tissue Distribution | 2 | 2014 | 318 | 0.190 |
Why?
| | Cytokines | 5 | 2025 | 2070 | 0.190 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 559 | 0.190 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 25 | 0.190 |
Why?
| | Indoles | 1 | 2025 | 406 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 112 | 0.180 |
Why?
| | Nephritis | 1 | 2021 | 24 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 9 | 0.180 |
Why?
| | Fetal Diseases | 1 | 2023 | 173 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2021 | 508 | 0.180 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.180 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 303 | 0.180 |
Why?
| | Child | 9 | 2023 | 21760 | 0.180 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 75 | 0.180 |
Why?
| | Calcium Channels, T-Type | 1 | 2022 | 96 | 0.170 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.170 |
Why?
| | Vascular Stiffness | 3 | 2021 | 494 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 152 | 0.170 |
Why?
| | Middle Aged | 16 | 2025 | 33226 | 0.170 |
Why?
| | Niacinamide | 1 | 2021 | 82 | 0.170 |
Why?
| | Databases, Genetic | 1 | 2022 | 239 | 0.170 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.170 |
Why?
| | Methionine | 1 | 2021 | 160 | 0.170 |
Why?
| | Benzamides | 3 | 2009 | 209 | 0.160 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2020 | 37 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 407 | 0.160 |
Why?
| | Nephrectomy | 1 | 2021 | 156 | 0.160 |
Why?
| | Cannabidiol | 1 | 2022 | 123 | 0.160 |
Why?
| | Pain | 1 | 2025 | 750 | 0.160 |
Why?
| | Vasodilation | 3 | 2018 | 497 | 0.160 |
Why?
| | Adolescent | 9 | 2021 | 21471 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 78 | 0.160 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 17 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 87 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 36 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 298 | 0.150 |
Why?
| | Brain | 2 | 2013 | 2711 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 34 | 0.150 |
Why?
| | Vitamin D | 2 | 2019 | 396 | 0.150 |
Why?
| | Blood Proteins | 1 | 2020 | 245 | 0.150 |
Why?
| | Glucose | 2 | 2017 | 1029 | 0.150 |
Why?
| | Homocysteine | 1 | 2019 | 156 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 55 | 0.150 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2020 | 181 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 329 | 0.140 |
Why?
| | Double-Blind Method | 5 | 2023 | 1904 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 420 | 0.140 |
Why?
| | 5'-Nucleotidase | 1 | 2018 | 40 | 0.140 |
Why?
| | Phenylpropionates | 1 | 2017 | 20 | 0.140 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 47 | 0.140 |
Why?
| | Phenotype | 3 | 2022 | 3148 | 0.140 |
Why?
| | Sex Characteristics | 2 | 2013 | 766 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 202 | 0.140 |
Why?
| | Therapies, Investigational | 1 | 2017 | 17 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 278 | 0.140 |
Why?
| | Complement Factor B | 1 | 2018 | 109 | 0.140 |
Why?
| | Terbutaline | 1 | 2017 | 8 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 336 | 0.140 |
Why?
| | Endothelins | 1 | 2017 | 63 | 0.140 |
Why?
| | Cell Cycle | 2 | 2011 | 600 | 0.140 |
Why?
| | Pyridazines | 1 | 2017 | 56 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 119 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 92 | 0.130 |
Why?
| | Protein Kinases | 2 | 2017 | 304 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 698 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 79 | 0.130 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2018 | 194 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 149 | 0.130 |
Why?
| | Receptors, Calcitriol | 1 | 2017 | 55 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 183 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2018 | 246 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 288 | 0.130 |
Why?
| | Brachial Artery | 4 | 2019 | 203 | 0.130 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.130 |
Why?
| | Drug Synergism | 2 | 2014 | 368 | 0.120 |
Why?
| | Calcineurin Inhibitors | 2 | 2014 | 73 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1156 | 0.120 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.120 |
Why?
| | Breast | 1 | 2017 | 155 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2013 | 98 | 0.120 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Extracellular Space | 1 | 2016 | 119 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 241 | 0.120 |
Why?
| | Premature Birth | 1 | 2019 | 334 | 0.120 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.120 |
Why?
| | Transplant Recipients | 1 | 2017 | 183 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 1999 | 0.120 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 40 | 0.120 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 43 | 0.120 |
Why?
| | Reperfusion Injury | 1 | 2018 | 277 | 0.120 |
Why?
| | Therapeutic Equivalency | 2 | 2017 | 30 | 0.120 |
Why?
| | Enzyme Activation | 1 | 2017 | 815 | 0.120 |
Why?
| | Fishes | 1 | 2016 | 110 | 0.120 |
Why?
| | Postoperative Period | 1 | 2016 | 338 | 0.120 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 392 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 521 | 0.120 |
Why?
| | Diet, Sodium-Restricted | 1 | 2015 | 36 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 177 | 0.110 |
Why?
| | Biological Availability | 2 | 2017 | 133 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 639 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 139 | 0.110 |
Why?
| | Serine | 1 | 2015 | 141 | 0.110 |
Why?
| | Organ Size | 1 | 2015 | 472 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 425 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.110 |
Why?
| | Tidal Volume | 1 | 2014 | 87 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2018 | 895 | 0.110 |
Why?
| | Macrophages, Alveolar | 2 | 2016 | 392 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 638 | 0.110 |
Why?
| | Respiration, Artificial | 2 | 2018 | 627 | 0.110 |
Why?
| | Aging | 2 | 2015 | 1849 | 0.110 |
Why?
| | Cannabis | 1 | 2021 | 495 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 23 | 0.100 |
Why?
| | Cattle | 1 | 2016 | 982 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 303 | 0.100 |
Why?
| | Everolimus | 2 | 2012 | 88 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 328 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1301 | 0.100 |
Why?
| | Lung | 3 | 2022 | 4035 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 106 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2371 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2060 | 0.100 |
Why?
| | Pilot Projects | 4 | 2023 | 1730 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 370 | 0.100 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 625 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 54 | 0.100 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 11 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 56 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 74 | 0.100 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.100 |
Why?
| | K562 Cells | 2 | 2009 | 91 | 0.100 |
Why?
| | Gluconeogenesis | 1 | 2012 | 79 | 0.100 |
Why?
| | Endothelial Cells | 2 | 2018 | 784 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 101 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5530 | 0.090 |
Why?
| | Nicorandil | 1 | 2012 | 11 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 95 | 0.090 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2809 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 130 | 0.090 |
Why?
| | Regression Analysis | 2 | 2012 | 1007 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 618 | 0.090 |
Why?
| | Androgens | 1 | 2013 | 184 | 0.090 |
Why?
| | Phosphates | 1 | 2012 | 180 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 216 | 0.090 |
Why?
| | Glucuronides | 1 | 2011 | 18 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Aged | 7 | 2025 | 23803 | 0.090 |
Why?
| | Cytoskeleton | 1 | 2012 | 190 | 0.090 |
Why?
| | Fatty Acids | 1 | 2014 | 446 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 3258 | 0.090 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 203 | 0.090 |
Why?
| | Models, Animal | 1 | 2013 | 384 | 0.090 |
Why?
| | Artifacts | 1 | 2011 | 127 | 0.090 |
Why?
| | Serotonin | 2 | 2024 | 321 | 0.080 |
Why?
| | Cell Survival | 2 | 2012 | 1124 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 59 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 841 | 0.080 |
Why?
| | Drugs, Generic | 1 | 2010 | 23 | 0.080 |
Why?
| | Cross Reactions | 1 | 2010 | 130 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 365 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 180 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 97 | 0.080 |
Why?
| | Brain Ischemia | 1 | 2013 | 339 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2014 | 1189 | 0.080 |
Why?
| | Drug Approval | 1 | 2010 | 86 | 0.080 |
Why?
| | Heart Ventricles | 2 | 2024 | 738 | 0.080 |
Why?
| | Reference Standards | 1 | 2009 | 183 | 0.080 |
Why?
| | Risk Assessment | 1 | 2018 | 3446 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2013 | 4136 | 0.080 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 49 | 0.080 |
Why?
| | Oncogenes | 1 | 2009 | 116 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1747 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1923 | 0.070 |
Why?
| | Lysosomes | 2 | 2021 | 144 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2017 | 547 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 300 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 588 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1746 | 0.070 |
Why?
| | Astrocytes | 1 | 2010 | 210 | 0.070 |
Why?
| | Phospholipids | 1 | 2009 | 219 | 0.070 |
Why?
| | Lactic Acid | 1 | 2009 | 306 | 0.070 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 522 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 621 | 0.070 |
Why?
| | Apoptosis | 3 | 2012 | 2542 | 0.070 |
Why?
| | Fibrosis | 2 | 2021 | 542 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 182 | 0.070 |
Why?
| | Allergens | 1 | 2010 | 394 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 171 | 0.060 |
Why?
| | Drug Monitoring | 1 | 2008 | 208 | 0.060 |
Why?
| | Nucleotides | 1 | 2007 | 125 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1096 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 42 | 0.060 |
Why?
| | Estradiol | 2 | 2020 | 519 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 407 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2064 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1299 | 0.060 |
Why?
| | Pulse Wave Analysis | 2 | 2018 | 272 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2024 | 406 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1680 | 0.060 |
Why?
| | Palliative Care | 2 | 2024 | 812 | 0.060 |
Why?
| | Kynurenic Acid | 1 | 2024 | 20 | 0.060 |
Why?
| | Isomerism | 1 | 2024 | 55 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2898 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 10363 | 0.050 |
Why?
| | Blood Pressure | 3 | 2019 | 1786 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1873 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1124 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 91 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3023 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 149 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 319 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2013 | 55 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1022 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 76 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 400 | 0.050 |
Why?
| | Steroids | 1 | 2022 | 157 | 0.050 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 37 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2855 | 0.050 |
Why?
| | Pregnancy | 3 | 2019 | 6736 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 139 | 0.040 |
Why?
| | Rats, Inbred Lew | 2 | 2012 | 113 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.040 |
Why?
| | Drug Stability | 2 | 2011 | 160 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 81 | 0.040 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 79 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 62 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2020 | 27 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 167 | 0.040 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2020 | 25 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2022 | 201 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 5688 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 125 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 141 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 131 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 307 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1256 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.040 |
Why?
| | Molecular Structure | 2 | 2014 | 493 | 0.040 |
Why?
| | Pulmonary Veins | 1 | 2020 | 102 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 81 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 62 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 783 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 88 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1279 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 155 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Reference Values | 2 | 2013 | 797 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 182 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 486 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 71 | 0.040 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 39 | 0.040 |
Why?
| | Rewarming | 1 | 2018 | 20 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 75 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2156 | 0.030 |
Why?
| | Position-Specific Scoring Matrices | 1 | 2017 | 2 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 185 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 965 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 182 | 0.030 |
Why?
| | Birth Weight | 1 | 2020 | 508 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 512 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 143 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 280 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 207 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 367 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 135 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1073 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 73 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 222 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 348 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 42 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 374 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2015 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 572 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 476 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 682 | 0.030 |
Why?
| | Aldehydes | 1 | 2016 | 144 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 901 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 409 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 57 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 321 | 0.030 |
Why?
| | Safety | 1 | 2017 | 343 | 0.030 |
Why?
| | Larva | 1 | 2016 | 235 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 22 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 18 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 253 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 832 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 309 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 391 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 582 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 84 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1635 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 65 | 0.030 |
Why?
| | Prognosis | 2 | 2013 | 3931 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 90 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1484 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 125 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 12 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1540 | 0.030 |
Why?
| | Binding Sites | 1 | 2017 | 1310 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 122 | 0.030 |
Why?
| | Dihydrotestosterone | 1 | 2013 | 43 | 0.030 |
Why?
| | Orchiectomy | 1 | 2013 | 73 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 10952 | 0.030 |
Why?
| | Altitude | 1 | 2017 | 465 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2015 | 476 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 50 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 317 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 40 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 171 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 690 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 203 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 73 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 347 | 0.020 |
Why?
| | Streptozocin | 1 | 2012 | 22 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1062 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2013 | 149 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 192 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 175 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1774 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 576 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 196 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 132 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 246 | 0.020 |
Why?
| | Transplantation | 1 | 2011 | 35 | 0.020 |
Why?
| | Podocytes | 1 | 2012 | 67 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 573 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 648 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1382 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 82 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 225 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 266 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2223 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 604 | 0.020 |
Why?
| | Daucus carota | 1 | 2010 | 1 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 193 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 619 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 380 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 22 | 0.020 |
Why?
| | Buffers | 1 | 2010 | 56 | 0.020 |
Why?
| | Graft Survival | 1 | 2012 | 523 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 878 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 391 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 156 | 0.020 |
Why?
| | Antigens, Plant | 1 | 2010 | 54 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1780 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2416 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1278 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 23 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 15536 | 0.020 |
Why?
| | Plant Proteins | 1 | 2010 | 114 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 362 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 392 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 9 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 839 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 80 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 200 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 134 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 159 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2009 | 144 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2463 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1867 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 873 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 338 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 439 | 0.020 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 971 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2139 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1872 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2851 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2900 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4542 | 0.010 |
Why?
| | Neurons | 1 | 2013 | 1586 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 407 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2574 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 2008 | 569 | 0.010 |
Why?
| | United States | 1 | 2010 | 14945 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|